Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.

Iain B McInnesKoji KatoMarina MagreyJoseph F MerolaKishimoto MitsumasaCésar Pacheco-TenaDerek HaalandLiang ChenYuanyuan DuanPatrick ZuegerJohn LiuRalph LippeAileen L PanganFranck Behrens

Published in: RMD open (2021)

Efficacy across various domains of PsA were maintained with upadacitinib 15 mg and 30 mg through week 56 with no new safety signals observed.

Keyphrases

prostate cancer
radical prostatectomy
electronic health record
randomized controlled trial
clinical trial
big data
placebo controlled
stem cells
mesenchymal stem cells
smoking cessation
data analysis
cell therapy
study protocol